Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03190278 is registered in ClinicalTrials.gov with Cellectis S.A. as lead sponsor.

NCT NCT03190278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Cellectis S.A.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 19, 2017
Completion date
December 31, 2025
Enrollment
29 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia